Second Century Ventures Announces Seven Companies Selected for 2023 REACH UK Technology Scale-Up Program
London, March 13, 2023 (GLOBE NEWSWIRE) -- Second Century Ventures, the strategic investment arm of the National Association of Realtors® and the most active global real estate technology fund, announced today the acceptance of seven companies to the 2023 REACH UK program.
Now entering its third year in the UK, the award-winning program continues to build on the successful strategic partnership with Propertymark – the UK’s leading professional body for property personnel, representing members who practise from more than 15,000 offices in all aspects of property services. REACH UK is designed to help technology companies scale their growth and create lasting impact across multiple real estate verticals worldwide.
“We are excited to welcome these innovators to our global portfolio, which has grown to more than 200 companies,” said Tyler Thompson, managing partner of Second Century Ventures. “These companies offer an impressive range of diverse solutions that address the most pressing challenges of the real estate industry, from energy savings to housing affordability. We are excited about the growth 2023 will bring for these entrepreneurs and their respective technologies.”
The companies selected for the 2023 REACH UK program were handpicked for their groundbreaking technologies and potential to impact the industry. These businesses provide technology serving a diverse range of market segments, helping real estate professionals to become more efficient, enhance business capabilities through the use of data, and address key challenges facing global markets such as housing affordability and carbon dioxide (CO2) emissions.
The seven companies selected for the 2023 REACH UK program include:
- Tweaq: Data-driven solutions for commercial portfolio owners and operators helping to make buildings safer and smarter by reducing cross contamination at points of entry and decreasing capital expenditure through actionable insights.
- CrowdToLive: Debt free, home financing solution, solving housing affordability challenges via connecting home buyers with buy-to-let investors in a shared ownership structure.
- Bisly: Intelligent building solution helping to reduce CO2 emissions and energy consumption for residential, commercial and hospitality sectors.
- Hococo: Tenant experience and operations SaaS solution for residential property owners and operators helping to improve net operating income and create vibrant communities.
- Grand Bequest: B Corp certified, circular economy platform helping local communities, councils, and lenders to redevelop and put vacant and underutilised buildings back into use.
- Verv: Intelligent solutions helping asset managers to reduce CO2 emissions and save up to 30% in operating costs by eradicating energy waste in air conditioning, heat pumps and other equipment.
- Yuno: SaaS solution helping private rented sector stakeholders to navigate complex localised legislation, reduce risk and drive growth.
“Working with REACH UK gives us an exciting opportunity to be at the forefront of digital innovation in the property industry,” said Nathan Emerson, CEO, Propertymark. “We are able to feed in what professionals need, and our agents get to see the latest solutions coming through that will change the way they work.”
REACH UK will offer its 2023 program participants a robust curriculum, including education, mentorship, exclusive networking opportunities and significant exposure to the global real estate marketplace. Learn more about the companies selected for the REACH UK program and how you can get involved by following REACH UK news on LinkedIn.
About NAR
The National Association of Realtors® is America's largest trade association, representing more than 1.5 million members involved in all aspects of the residential and commercial real estate industries. The term Realtor® is a registered collective membership mark that identifies a real estate professional who is a member of the National Association of Realtors® and subscribes to its strict Code of Ethics.
About REACH
REACH is a unique technology scale-up program created by Second Century Ventures, the most active global fund in real estate technology. Backed by the National Association of Realtors®, Second Century Ventures leverages the association's more than 1.5 million members and an unparalleled network of executives within real estate and adjacent industries. The REACH program helps technology companies scale across the real estate vertical and its adjacent markets through education, mentorship and market exposure. For more on REACH, visit https://nar-reach.com/.
AboutPropertymark
Propertymark is the UK's leading professional body for estate and letting agents, commercial agents, auctioneers, valuers and inventory providers, comprising nearly 17,500 members. Propertymark is member-led with a Board which is made up of practising agents who ensure the organisation works closely with its members to set professional standards through regulation, accredited and recognised qualifications, an industry-leading training programme and mandatory Continuing Professional Development.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are